Clinical trials: Refractory Lymphoma
Refractory Cutaneous T-cell Lymphoma
Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)
This is a multicenter, randomized, open-label, Phase IV study to assess the efficacy, tolerability, and safety of 2 initial dose levels of bexarotene capsules in participants with refractory CTCL.
- Trial name
- NCT01007448
- Testing
- Bexarotene
- Where
- 17 sites in United States
- Volunteers
- 59 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
This is a Phase 1, open-label, multicenter study evaluating the safety and PK profile of ABT-199 under a once daily dosing schedule.
- Trial name
- NCT01328626
- Testing
- ABT-199
- Where
- 10 sites in United States, Australia
- Volunteers
- 222 people
- Sponsor
- AbbVie
Follicular Lymphoma
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study
This study is planned to prospectively observe and verify the efficacy and safety of induction therapy with obinutuzumab in combination with lenalidomide followed by maintenance therapy with obinutuzumab and lenalidomide in…
- Trial name
- NCT05846763
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Hodgkin Lymphoma
Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma
The purpose of this trial is 1. to determine the recommended dose of everolimus for a subsequent Phase II trial 2. to determine the efficacy of everolimus plus DHAP
- Trial name
- HD-R3i (NCT01453504)
- Testing
- DHAP, Everolimus
- Where
- Germany
- Volunteers
- 73 people
- Sponsor
- University of Cologne
Refractory Diffuse Large B Cell Lymphoma
Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
The primary objective of phase 1 is to evaluate the safety of KTE-C19 and atezolizumab combination regimens. The primary objective of phase 2 is to evaluate the efficacy of KTE-C19 and atezolizumab, as measured by complete…
- Trial name
- ZUMA-6 (NCT02926833)
- Testing
- KTE-C19, Atezolizumab, Cyclophosphamide
- Where
- 5 sites in United States
- Volunteers
- 37 people
- Sponsor
- Kite, A Gilead Company
Refractory or Relapsed Non-Hodgkin's Lymphoma
Radiomics and Metabolomics in the Follow-up of CAR T-cells for Refractory or Relapsed Non-Hodgkin's Lymphoma
This is an interventionnal pilot study to investigate whether 18FDG radiomics or serum metabolomic signatures could be predictive or prognostic factors in the follow-up of patients receiving CAR T-cell therapy for refractory…
- Trial name
- CART-Omic (NCT05422521)
- Testing
- blood samples and 18FDG PET-CT exams
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL
This is a single arm, single-center, non-randomized study to evaluate the safety and efficacy of C-CAR011 in relapsed or refractory B cell Non-Hodgkin Lymphoma (NHL).
- Trial name
- NCT03299738
- Testing
- C-CAR011
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai AbelZeta Ltd.
Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
This phase I trial studies pretargeted radioimmunotherapy and donor peripheral blood stem cell transplant employing fludarabine phosphate and total-body irradiation (TBI) to treat patients with high-risk acute myeloid leukemia…
- Conditions
- Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia
- Trial name
- NCT00988715
- Testing
- Pretargeted Radioimmunotherapy, Cyclosporine, Mycophenolate Mofetil
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Fred Hutchinson Cancer Center
Mantle Cell Lymphoma
Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy
The purpose of this study is to evaluate the efficacy and safety of ibrutinib versus temsirolimus in patients with relapsed or refractory mantle cell lymphoma who received at least 1 prior chemotherapy regimen.
- Trial name
- NCT01646021
- Testing
- Ibrutinib, Temsirolimus
- Where
- 92 sites in Belgium, Brazil and 19 more
- Volunteers
- 280 people
- Sponsor
- Janssen Research & Development, LLC
Lymphoma, Large-Cell, Diffuse
PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma
This is a phase II open label study to assess the efficacy and safety of PTK787/ZK222584 in adults with relapsed or refractory diffuse large cell lymphoma (DLCL). All subjects will receive PTK787/ZK222584.
- Trial name
- NCT00511043
- Testing
- PTK787
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- David Rizzieri, MD
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well vemurafenib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with BRAF V600 mutations that have spread to other places in the body…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Ependymoma
- Trial name
- NCT03220035
- Testing
- Laboratory Biomarker Analysis, Vemurafenib
- Where
- 116 sites in United States, Puerto Rico
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoid, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic Leukemia
The study objectives are to evaluate the safety and efficacy of the oral administration of lenalidomide in combination with dexamethasone in the treatment of adult patients with refractory or relapsed non-Ph+ B-cell lineage acute…
- Trial name
- RV-405 LAL (NCT01116193)
- Testing
- Lenalidomide plus dexamethasone
- Where
- 4 sites in France
- Volunteers
- 10 people
- Sponsor
- Institut de Cancérologie de la Loire
Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia/Lymphoma
CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies
The objective of this study was to evaluate the safety and efficacy of CD180 CART cells in the treatment of patients with relapsed/refractory CD180-positive hematological malignancies.
- Trial name
- NCT07106749
- Testing
- CD180 CART
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Chronic Myeloproliferative Disorders, Leukemia
12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004058
- Testing
- tetradecanoylphorbol acetate
- Where
- United States
- Sponsor
- University of Medicine and Dentistry of New Jersey
Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)
The purpose of this study is to test any good or bad effects of the study drug called of ibrutinib (also known as Imbruvica™). At this stage of this trial, the study is investigating whether Ibrutinib can be incorporated into the…
- Trial name
- NCT02315326
- Testing
- Ibrutinib, HD- Methotrexate (MTX), Rituximab + HD- Methotrexate (MTX)
- Where
- 7 sites in United States
- Volunteers
- 93 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diffuse, Large B-Cell, Lymphoma
Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
To assess the potential efficacy (in terms of objective response) of single agent copanlisib in patients with relapsed or refractory Diffuse large B-cell lymphoma (DLBCL) and assess the relationship between efficacy and a…
- Trial name
- NCT02391116
- Testing
- Copanlisib (Aliqopa, BAY80-6946)
- Where
- 32 sites in Australia, Belgium and 8 more
- Volunteers
- 67 people
- Sponsor
- Bayer
Lymphoma Diffuse Large B-cell, Leukemia and Lymphoma
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
This study is testing Allo-QuadCAR01-T, a new off-the-shelf CAR-T therapy for people with hard-to-treat B-cell cancers. Unlike current CAR-T treatments that use a patient's own cells, this therapy uses donor cells that are ready…
- Conditions
- Lymphoma Diffuse Large B-cell, Leukemia and Lymphoma, Leukemia Relapse, Lymphoma Receiving CAR-T Therapy
- Trial name
- QUADvance (NCT07284433)
- Testing
- Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), Allo-QuadCAR01-T
- Where
- 13 sites in United States, Germany
- Volunteers
- 178 people
- Sponsor
- AvenCell Therapeutics, Inc.
B-ALL, B-NHL
JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia
This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory B cell lymphoma / leukemia.
- Trial name
- NCT06689917
- Testing
- JY231 Injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Tongji Hospital
Mantle Cell Lymphoma
BTK Inhibitor DTRMWXHS-12 in Mantle Cell Lymphoma
The Primary Objective is to evaluate the safety and tolerability of the DTRMWXHS-12 capsule in patients with relapsed/refractory MCL and recommend the dose and dosing method (RP2D) used in phase II study.
- Trial name
- NCT03836768
- Testing
- DTRMWXHS-12
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang DTRM Biopharma
Acute Lymphoblastic Leukemia, Precursor B-Cell Lymphoblastic Leukemia
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
This is a pilot study using decitabine and vorinostat before and during chemotherapy with vincristine, dexamethasone, mitoxantrone, and peg-asparaginase in pediatric patients with acute lymphoblastic leukemia (ALL).
- Conditions
- Acute Lymphoblastic Leukemia, Precursor B-Cell Lymphoblastic Leukemia, Precursor T-Cell Lymphoblastic Leukemia
- Trial name
- NCT01483690
- Testing
- Decitabine, Vorinostat, Vincristine
- Where
- 28 sites in United States, Australia
- Volunteers
- 23 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium